Hybio Pharmaceutical's (SHE:300199) unit, Gansu Chengji Biopharmaceutical, received the drug registration certificate from China's National Medical Products Administration for carboprost tromethamine injection, according to a Shenzhen bourse filing on Tuesday.
The drug is used to treat postpartum hemorrhage caused by uterine atony.
The pharmaceutical company's shares fell 2% during the afternoon trade.